I. Henderson

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

D. Berry, E. Winer, E. Perez, 2006, JAMA.

Primary cerebral venous thrombosis in patients with cancer--a rarely diagnosed paraneoplastic syndrome. Report of three cases and review of the literature.

W. Hickey, I. Henderson, D. Dawson, 1982, The American journal of medicine.

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

D Tripathy, C. Hudis, L. Norton, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Assessment of left ventricular contractility in patients receiving doxorubicin.

S. Colan, S. Papish, I. Henderson, 1983, Annals of Internal Medicine.

Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children

S. Sallan, I. Henderson, K. Borow, 1981, Cancer.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer

Sharyl J. Nass, Joyce C. Lashof, S. Nass, 2001 .

COMMITTEE ON TECHNOLOGIES FOR THE EARLY DETECTION OF BREAST CANCER

Sharyl J. Nass, Joyce C. Lashof, S. Nass, 2001 .

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

M. Piccart-Gebhart, I. Henderson, 2005, Clinical breast cancer.

Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.

I. Henderson, 2004, Seminars in oncology.

Mink cell line Mv 1 Lu (CCL 64). Focus formation and the generation of "nonproducer" transformed cell lines with murine and feline sarcoma viruses.

I. Henderson, G. Todaro, M. Lieber, 1974, Virology.

Adjuvant systemic therapy: State of the art, 1989

I. Henderson, 1989, Breast Cancer Research and Treatment.

Conservative surgery and radiotherapy for early breast cancer

S. Schnitt, A. Recht, S. Love, 1986, Cancer.

Adjuvant systemic therapy for patients with node‐negative tumors

S. Love, L. Parker, J. Garber, 1990, Cancer.

Chemotherapy of breast cancer

I. Henderson, 1989 .

Adjuvant chemotherapy for early breast cancer.

I. Henderson, 1990, British Journal of Cancer.

Adjuvant chemotherapy of breast cancer.

I. Henderson, J. Breitmeyer, 1990, The Surgical clinics of North America.

Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.

C. Shapiro, R. Gelman, D. Hayes, 1993, Journal of the National Cancer Institute.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

The relationship between prognostic and predictive factors in the management of breast cancer

I. Henderson, I. Craig Henderson, Anthony J. Patek, 2004, Breast Cancer Research and Treatment.

Cancer of the breast: the past decade (second of two parts).

I. Henderson, G. Canellos, 1980, The New England journal of medicine.

Management of metastatic breast cancer

I. Henderson, K. Wong, 2004, World Journal of Surgery.

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1999, Seminars in oncology.

A rose is no longer a rose.

I. Henderson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.

G. Rosner, R. Schilsky, M. Ratain, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).

M. Ratain, C. Shapiro, I. Henderson, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Adjuvant chemotherapy is not for everyone

I. Henderson, 2010, Breast Cancer Research and Treatment.

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

D. Berry, E. Winer, C. Hudis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant systemic therapy for early breast cancer.

I. Henderson, C. Henderson, 1987, Current Problems in Cancer.

Structural and functional effects of adriamycin on cardiac cells in vitro.

T. Lampidis, I. Henderson, M. Israel, 1980, Cancer research.

Fall in Liver DNA Polymerase Activity in Cortisone-treated Rats

I. Henderson, J. Loeb, 1970, Nature.

Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma.

S. Schnitt, A. Recht, J. Connolly, 1989, International journal of radiation oncology, biology, physics.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

D. Berry, L. Norton, L. Dressler, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy.

B. Cady, J. Harris, I. Henderson, 1987, Cancer.

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

D. Berry, E. Winer, C. Hudis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

D. Berry, L. Norton, D. Cowan, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541.

D. Berry, M. Roach, D. Hayes, 1997, The cancer journal from Scientific American.

Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

S. L. Mann, Lawrence S. Cohen, J. Manson, 2022, The American Journal of Clinical Nutrition.

Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?

I. Henderson, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer.

S. London, F. Sacks, M. Stampfer, 1993, Journal of the National Cancer Institute.

Comprehensive management of disseminated breast cancer

J. Garber, D. Hayes, J. Harris, 1990, Cancer.

Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer.

C. Shapiro, D. Hayes, J. Wright, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Analyzing local and distant recurrence (Reply)

R. Gelber, C. Coleman, R. Gelman, 1990 .

Chest wall recurrence of ductal carcinoma in situ of the breast after mastectomy

S. Schnitt, Jay R. Harris, D. Fisher, 1993, Cancer.

New treatments for breast cancer.

I. Henderson, G. Smith, 1996, Seminars in Oncology.

Can we abandon anthracyclines for early breast cancer patients?

I. Henderson, 2011, Oncology.

Biologic variations of tumors

I. Henderson, 1992 .

Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.

R. Gelman, D. Hayes, D. Kufe, 1988, Cancer research.

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

D. Berry, L. Norton, D. Hayes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer.

P. Stomper, I. Henderson, M. Jochelson, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

I. Henderson, S. Nussbaum, J. Younger, 1993, The American journal of medicine.

The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy.

A. Recht, R. Gelman, J. Harris, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.

Anthony J. Guidi, D. Berry, L. Norton, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Integration of Radiotherapy and Chemotherapy in the Treatment of Early Breast Cancer

Jay R. Harris, D. Hayes, S. Come, 1989 .

Comparison of CAI 5-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer 1

R. Gelman, D. Hayes, D. Kufe, 2006 .

Comparison of CAI5-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer1

R. Gelman, D. Hayes, D. Kufe, 2006 .

The nature of the benefit.

I. Henderson, 1992, Cancer treatment and research.

Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.

L. Norton, C. Cirrincione, I. Henderson, 1999, American journal of clinical oncology.

Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.

K. Anderson, A. Jakubowiak, A. Krishnan, 2007 .

Serial studies of cardiac function in patients receiving adriamycin.

I. Henderson, R. Blum, N. Jaffe, 1978, Cancer treatment reports.

Adriamycin and the heart.

I. Henderson, E. Frei, T. Frei, 1979, The New England journal of medicine.

Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.

I. Henderson, M. Israel, M. Garnick, 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: updated results of a prospective randomized trial

J. Bellon, A. Recht, R. Gelman, 2001 .

Treatment of metastatic breast cancer: present and future prospects.

C. Shapiro, D. Hayes, I. Henderson, 1995, Seminars in oncology.

Dose-response in the treatment of breast cancer: a critical review.

R. Gelman, D. Hayes, I. Henderson, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A therapeutic trial of maytansine.

L. Parker, R. Mayer, I. Henderson, 1978, Cancer clinical trials.

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer: Swain SM, Jeong J-H, Geyer CE Jr, et al (Washington Cancer Inst at Washington Hosp Ctr, DC; Univ of Pittsburgh, PA; et al) N Engl J Med 362:2053-2065, 2010§

I. Henderson, 2011 .

Second malignancies from adjuvant chemotherapy? Too soon to tell.

R. Gelman, I. Henderson, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer therapy--the price of success.

I. Henderson, 1992, The New England journal of medicine.

Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.

I. Henderson, M. Israel, M. Garnick, 1979, Cancer treatment reports.

Primary radiation therapy for locally advanced breast cancer

A. Recht, Jay R. Harris, L. Parker, 1987, Cancer.

Paclitaxel in the adjuvant setting: results so far are inconclusive.

G. Sledge, I. Henderson, A. D'Orazio, 2001, Clinical breast cancer.

Breast carcinoma metastatic to a meningioma. Case report and review of the literature.

J. Connolly, P. Stomper, J. Harris, 1989, Archives of internal medicine.

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

The effect of timing of primary breast irradiation and chemotherapy on the cosmetic results

Jay R. Harris, S. Come, I. Henderson, 1984 .

A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).

K. Anderson, A. Jakubowiak, A. Krishnan, 2006 .

Paradigmatic shifts in the management of breast cancer.

I. Henderson, 1995, The New England journal of medicine.

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

H. Cohen, D. Berry, E. Winer, 2005, JAMA.

Improved methodology for analyzing local and distant recurrence.

R. Gelber, C. Coleman, R. Gelman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis following breast recurrence after conservative surgery (S) and radiotherapy (RT) for early stage breast carcinoma

S. Schnitt, B. Silver, A. Recht, 1987 .

PharmacodynamicMarkers of Perifosine Efficacy

G. Mills, M. Carey, Yiling Lu, 2007 .

New agents and new medical treatments for advanced breast cancer.

D. Hayes, J. Harris, S. Come, 1987, Seminars in oncology.

Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.

R. Gelman, I. Henderson, G. Canellos, 1981, Cancer treatment reports.

TAMOXIFEN AND AMINOGLUTETHIMIDE IN ADVANCED BREAST CANCER

R. Gelman, I. Henderson, H. A. Salhanick, 1982, Cancer research.

Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

R. Figlin, I. Henderson, J. Stephenson, 2008 .

Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)

I. Henderson, J. Stephenson, L. Campos, 2007 .

CAF in metastatic breast cancer: standard therapy or another effective regimen?

D. Hayes, I. Henderson, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer of the breast: the past decade (first of two parts).

I. Henderson, G. Canellos, 1980, The New England journal of medicine.

Development of PEGylated Liposomes

I. Henderson, 2011 .

Partial purification and characterization of the SV40 T antigen.

D. Livingston, I. Henderson, 1974, Cell.

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.

R. Bast, L. Parker, J. Kirkwood, 1980, The American journal of medicine.

Suppression of liver DNA synthesis by cortisone.

I. Henderson, R. E. Fischel, J. Loeb, 1971, Endocrinology.

The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer.

S Hellman, J. Harris, S. Hellman, 1984, International journal of radiation oncology, biology, physics.

Chemotherapy for Node-Negative Breast Cancer

R. Epstein, I. Henderson, 1993 .

Pharmacodynamic Markers of Perifosine Efficacy

Yiling Lu, Gordon B. Mills, Vikas Kundra, 2007, Clinical Cancer Research.

Risk factors for breast cancer development

I. Henderson, 1993, Cancer.

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.

C. Shapiro, R. Gelman, D. Hayes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

I. Henderson, T. Woodcock, D. Henry, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.

D. Tripathy, B. Overmoyer, I. Henderson, 2005, Clinical breast cancer.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

E. Winer, C. Shapiro, N. Robert, 2004, Seminars in oncology.

How to Manage Complications of ADT

C. Flowers, W. Gradishar, E. Dees, 2018 .

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.

J. Bellon, A. Recht, R. Gelman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.

L. Norton, T. Fitzgerald, F. Laurie, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.

A. Recht, R. Gelman, D. Hayes, 1996, The New England journal of medicine.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

S. Martino, R. Livingston, W. Barlow, 2009, The Lancet.

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

R. Gray, M. Citron, N. Robert, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hexamethylmelamine use in the treatment of metastatic breast cancer.

C. Shapiro, I. Henderson, 1991, Cancer treatment reviews.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

D. Berry, E. Winer, C. Hudis, 2008, Cancer treatment reviews.

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.

D. Berry, E. Winer, R. Schilsky, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 )

D. Berry, M. Ellis, E. Winer, 2011 .

High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry.

D. Berry, J. Klein, H. Parnes, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB)

D. Berry, I. Henderson, R. Weiss, 2004, Breast Cancer Research and Treatment.

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

Larry Norton, Donald A Berry, D. Berry, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims From CALGB Breast Cancer Trial Participants (Companion to 9344)

Nicholas A. Christakis, N. Christakis, E. Lamont, 2006, Journal of the National Cancer Institute.

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Barbara L. Smith, D. Berry, E. Winer, 2004, The New England journal of medicine.

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

I. Henderson, I Craig Henderson, Vinona Bhatia, 2007, Expert review of anticancer therapy.

14 Sequencing of chemotherapy (CT) and radiotherapy (RT) following conservative surgery (CS) for patients with early-stage breast cancer: Results of a randomized trial

B. Silver, A. Recht, R. Gelman, 1995 .

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

D. Berry, L. Norton, L. Dressler, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.

G. Rosner, R. Schilsky, D. Hollis, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Diseases

Sauer, M. Sabel, I. Henderson, 1989, Springer Berlin Heidelberg.

What can a woman do about her risk of dying of breast cancer?

I. Henderson, 1990, Current problems in cancer.

Tamoxifen and Aminoglutethimide in Advanced Breast Cancer 1

R. Gelman, I. Henderson, S. Farber, 2006 .

Chemotherapy of breast cancer a general overview

I. Henderson, 1983, Cancer.

Ganglioneuropathy in rabbits and a rhesus monkey due to high cumulative doses of doxorubicin.

R. Bronson, I. Henderson, H. Fixler, 1982, Cancer treatment reports.

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.

D. Berry, L. Norton, J. Abrams, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

V. Georgoulias, C. Vogel, L. Alland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of chemotherapy in metastatic breast cancer.

J. Garber, I. Henderson, 1989, Hematology/oncology clinics of North America.

Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials.

S. Martino, J. Ingle, C. Osborne, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carotenoids, retinol, and vitamin E and risk of proliferative benign breast disease and breast cancer

W. Willett, S. London, M. Stampfer, 1992, Cancer Causes & Control.

Are breast cancers in young women qualitatively distinct?

I. Henderson, A. Patek, 1997, The Lancet.

Purchasing oncology services

K. Dickersin, T. Ades, D. Ballard, 2000 .

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Clinical Trial Service Unit (CTSU), Oxford, UK) Lancet 379:432-444, 2012§

I. Henderson, I. C. Henderson, 2013 .

Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: a US perspective

I. Henderson, Anjali S. Kumar, Vinona Bhatia, 2005, Breast Cancer Research.

Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its Encapsulation in Pegylated Liposomes

I. Henderson, P. Working, G. Colbern, 1999 .

Breast Cancer: Fundamentals of Evidence-Based Disease Management

I. Henderson, 2015 .

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

D. Berry, H. Parnes, L. Norton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)

D. Berry, E. Winer, L. Norton, 2009, Breast Cancer Research and Treatment.

Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure.

C. Coleman, S. Schnitt, A. Recht, 1989, International journal of radiation oncology, biology, physics.

Duration of therapy in adjuvant chemotherapy trials.

R. Gelman, J. Harris, I. Henderson, 1986, NCI monographs : a publication of the National Cancer Institute.

Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer

Sharyl J. Nass, Margie Patlak, Joyce C. Lashof, 2001 .

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma

I. Henderson, Antonius A. Miller, R. Navari, 1996, Cancer.

Rapporteur's report — treatment and response

I. Henderson, 1991, Breast Cancer Research and Treatment.

HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344.

S. Martino, L. Dressler, D. Weaver, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aminoglutethimide-induced hematologic toxicity: worldwide experience.

A. Buzdar, J. Ragaz, R. Santen, 1985, Cancer treatment reports.

Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.

J. Garber, R. Santen, I. Henderson, 1991, The Journal of clinical endocrinology and metabolism.

Phase II study of echinomycin in patients with advanced breast cancer: A report of cancer and leukemia group B protocol 8641

R. Schilsky, D. Faraggi, W. Wood, 1991, Investigational New Drugs.

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

Lawrence B Marks, Jinli Ma, Larry Norton, 2010, International journal of radiation oncology, biology, physics.

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

G. Rosner, R. Schilsky, L. Norton, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Esorubicin (4′‐Deoxydoxorubicin, NSC 267469) in Advanced Breast Cancer: A Phase II Study of the CALGB

W. Wood, N. Vogelzang, I. Henderson, 1990, American journal of clinical oncology.

Mitoxantrone use in breast cancer patients with elevated bilirubin

R. Elashoff, R. Chlebowski, I. Henderson, 1989, Breast Cancer Research and Treatment.

Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the breast

S. Schnitt, A. Recht, J. Connolly, 2005, Breast Cancer Research and Treatment.

Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

N. Christakis, E. Lamont, R. Schilsky, 2008, Medical care.

Essential drugs for cancer chemotherapy

N. Pavlidis, I. Henderson, S. Advani, 1994 .

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.

C. Shapiro, G. Demetri, R. Gelman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy treatments: chemotherapy for breast cancer

I. Henderson, 1992 .

Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.

R. Santen, I. Henderson, A. Lipton, 1987, The Journal of laboratory and clinical medicine.

Biologic variations of tumors.

I. Henderson, 1992, Cancer.

A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer

I. Henderson, T. Woodcock, G. Dukart, 2004, Investigational New Drugs.

Hormone-induced changes in liver DNA synthesis: effects of glucocorticoids and growth hormone on liver growth and DNA polymerase activity.

I. Henderson, J. Loeb, 1974, Endocrinology.

Adriamycin cardiotoxicity.

I. Henderson, E. Frei, 1980, American heart journal.

Less toxic treatment for advanced breast cancer.

I. Henderson, 1981, The New England journal of medicine.

Published in cooperation with Kaiser Foundation Health Plan and Southern California Permanente Medical Group.

S. Goodman, B. McNeil, B. Lo, 2006 .

Incidence of and treatment for ductal carcinoma in situ of the breast.

K. Kerlikowske, V. Ernster, J. Barclay, 1996, JAMA.

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

D. Berry, A. Thor, W. Wood, 1994, The New England journal of medicine.

Cancer in America, 2004

L. Bosserman, I. Henderson, 2004 .

Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)

I. Henderson, S. Chawla, R. Birch, 2008 .

Biologic variations of tumors

I. Henderson, 1992, Cancer.

Adjuvant therapy of breast cancer.

C. Shapiro, I. Henderson, 1994, Hematology/oncology clinics of North America.

Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

S. L. Mann, Lawrence S. Cohen, J. Manson, 2022, The American journal of clinical nutrition.

Conservative surgery and radiation therapy for early breast cancer: results, controversies, and unsolved problems.

S. Schnitt, A. Recht, S. Love, 1986 .

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

L. Norton, W. Wood, I. Henderson, 1994, The New England journal of medicine.

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

G. Rosner, E. Winer, R. Bast, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of bruceantin.

L. Parker, R. Mayer, I. Henderson, 1979, Cancer treatment reports.

Molecular cytogenetics of human breast cancer.

J W Gray, D Pinkel, J Isola, 1994, Cold Spring Harbor symposia on quantitative biology.

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

A. Jakubowiak, T. Zimmerman, P. Richardson, 2007 .

Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.

A. Jakubowiak, S. Lonial, Jeffrey N. Martin, 2007 .

Comprehensive management of disseminated breast cancer

D. Hayes, I. Henderson, J. Breitmeyer, 1990, Cancer.

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

Adjuvant therapy in node-negative breast cancer

W. McGuire, C. Osborne, J. Glick, 1989, Breast Cancer Research and Treatment.

Cancer control: introduction to a series of reports on strategies and approaches.

J. Stjernswärd, I. Henderson, K. Stanley, 1986, Bulletin of the World Health Organization.